SANGAMO THERAPEUTICS, INC. (SGMOQ)

0.16USD -5.29% (-0.01)

Over 5Y: +0.6%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

0.1 0.2
May Jun Jul Aug Sep

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.0
SBC / sales 21.6%
OE margin -283.4%
Oper. margin -357.5%
Accruals -55.0%
EBITDA margin -347.0%
FCF margin -261.8%
OCF margin -261.4%
Profit margin -356.9%
ROA -205.7%
ROCE -1808.8%
Gross margin —
OCF / EBIT —
ROE —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

4.8
EV/OE 0.37×
EV/Sales -1.1×
P/C 0.65×
FCF yield -134.0%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/B —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.1
RPO / sales 0.012×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

3.7
ND/EBITDA -2.9
Cash runway 1.1 yr
Debt payback 0.0 yr
Quick ratio 0.7×
F-score 2.6 pts
Cash / Debt —
Debt / Eq —
Equity / Assets —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales CAGR 4Y -22.7%
Sales/sh Y/Y -61.0%
Sales Q/Q -77.6%
Shares change +38.9%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.